Commentary: Expedited Regulatory Review of Low-Value Drugs

Lexchin has criticized Health Canada's recently published draft guidance on accelerated drug review, expressing concern over agency conflicts of interest and observing that priority review and notice of compliance with conditions correlate poorly with therapeutic benefit. Although agency operat...

Descripción completa

Detalles Bibliográficos
Autores principales: Darrow, Jonathan J., Beall, Reed F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Longwoods Publishing 2020
Materias:
Discussion and Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294442/
https://www.ncbi.nlm.nih.gov/pubmed/32538347
http://dx.doi.org/10.12927/hcpol.2020.26226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294442/
https://www.ncbi.nlm.nih.gov/pubmed/32538347
http://dx.doi.org/10.12927/hcpol.2020.26226

Ejemplares similares